肿瘤细胞治疗研究
英文原题：A CD123-specific chimeric antigen receptor augments anti-acute myeloid leukemia activity of Vγ9Vδ2 T cells.
A CD123-specific chimeric antigen receptor augments anti-acute myeloid leukemia activity of Vγ9Vδ2 T cells.
目的：探讨表达抗CD123嵌合抗原受体（CAR）的Vγ9Vδ2 T细胞是否可作为急性髓系白血病（AML）治疗的替代方案。
目的：探讨表达抗CD123嵌合抗原受体（CAR）的Vγ9Vδ2 T细胞是否可作为急性髓系白血病（AML）治疗的替代方案。材料与方法：将体外扩增的Vγ9Vδ2 T细胞电穿孔导入编码抗CD123 CAR的mRNA。通过体外细胞毒性、脱颗粒及细胞因子释放水平检测修饰后Vγ9Vδ2 T细胞的效应功能和特异性。采用NOD-SCID-γc-/-小鼠的KG1-luc异种移植模型分析体内功能。结果：修饰后的Vγ9Vδ2 T细胞在体外对AML细胞系和原代AML细胞均表现出显著增强的效应活性。在异种移植小鼠模型中，修饰后的Vγ9Vδ2细胞显示出增强的肿瘤控制能力。结论：表达抗CD123 CAR的Vγ9Vδ2 T细胞可能成为靶向AML的替代方法。
Aim: To investigate whether anti-CD123 chimeric antigen receptor (CAR)-expressing Vγ9Vδ2 T cells could be an alternative for acute myeloid leukemia (AML) treatment. Materials & methods: Ex vivo expanded Vγ9Vδ2 T cells were electroporated with anti-CD123 CAR-encoding mRNA. The effector function and specificity of the modified Vγ9Vδ2 T cells were examined by in vitro cytotoxicity, degranulation and cytokine release level. The in vivo function was analyzed using the xenograft KG1-luc model with NOD-SCID-γc-/- mice. Results: The modified Vγ9Vδ2 T cells exhibited significantly improved effector activities against both AML cell lines and primary AML cells in vitro . In the xenograft mouse model, the modified Vγ9Vδ2 cells displayed an enhanced tumor control potency. Conclusion: Anti-CD123 CAR-expressing Vγ9Vδ2 T cells may serve as an alternative way to target AML.
MEMBER ACCOUNT
登录成功会直接打开下一页。
